Evidence map›Paper›PMID 25104786›Full record

ReviewEuropean heart journal2014

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

Michele Senni, Walter J Paulus, Antonello Gavazzi, Alan G Fraser, Javier Díez, Scott D Solomon, Otto A Smiseth, Marco Guazzi, Carolyn S P Lam, Aldo P Maggioni and 13 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 6 pooled it
27.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 6 syntheses or guidelines pooled it, 353 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Autonomic Neuromodulation Acutely Ameliorates Left Ventricular Strain in Humans.Journal of cardiovascular translational research · 2019
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 19 institutions in 10 countries.

Michele SenniCardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Walter J PaulusInstitute for Cardiovascular Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Antonello GavazziCardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Alan G FraserWales Heart Research Institute, Cardiff University, Cardiff, UK.
Javier DíezDivision of Cardiovascular Sciences Centre for Applied Medical Research and Department of Cardiology and Cardiac Surgery, University of Navarra Clinic, University of Navarra, Pamplona, Spain.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Otto A SmisethInstitute for Surgical Research, Department of Cardiology, and Center for Cardiological Innovation, University of Oslo, Oslo, Norway.
Marco GuazziHeart Failure Unit, Department of Biomedical Sciences for Health, IRCCS Policlinico San Donato, University of Milano, Milan, Italy.
Carolyn S P LamNational University Health System, Singapore, Singapore.
Aldo P MaggioniANMCO Research Center, Florence, Italy.
Carsten TschöpeDepartment of Cardiology and Pneumology, Charité-University Medicine Berlin, Campus Benjamin Franklin, Germany.
Marco MetraCardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy.
Scott L HummelDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA Section of Cardiology, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI, USA.
Frank EdelmannDepartment of Cardiology and Pneumology, University of Göttingen, Göttingen, Germany.
Giuseppe AmbrosioDivision of Cardiology, University of Perugia School of Medicine, Perugia, Italy.
Andrew J Stewart CoatsMonash University, Melbourne, Australia University of Warwick, Conventry, UK.
Gerasimos S FilippatosAthens University Hospital Attikon, Athens, Greece.
Mihai GheorghiadeCenter for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Stefan D AnkerDepartment of Innovative Clinical Trials, University Medical Centre Gottingen, Gottingen, Germany Applied Cachexia Research, Department of Cardiology, Charite, Campus CVK, Berlin, Germany.
Daniel LevyFramingham Heart Study, Framingham, MA, USA Division of Cardiology, Boston University School of Medicine, Boston, MA, USA Center for Population Studies, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
Marc A PfefferCardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Wendy Gattis StoughDepartment of Clinical Research, Campbell University College of Pharmacy and Health Sciences, North Carolina, USA.
Burkert M PieskeDepartment of Cardiology, Medical University Graz, Ludwig-Boltzmann-Institute for Heart Failure Research, Auenbruggerplatz 15, 8010 Graz, Austria burkert.pieske@medunigraz.at.
Brigham and Women's Hospital · USCharité - Universitätsmedizin Berlin · DEOspedale Papa Giovanni XXIII · ITAmsterdam UMC Location VUmc · NLAnn Arbor VA Medical Center · USAssociazione Nazionale Medici Cardiologi Ospedalieri · ITCampbell University · USCardiff University · GBIRCCS Policlinico San Donato · ITNational Heart Lung and Blood Institute · USNational University Health System · SGNorthwestern University · USUniversidad de Navarra · ESUniversity General Hospital Attikon · GRUniversity of Brescia · ITUniversity of Göttingen · DEUniversity of Oslo · NOUniversity of Perugia · ITUniversity of Warwick · GB

Funding

Framingham Project/LevyZIAHL006001 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVY, DANIEL · 2009 to 2025
$51.1M
Diet and pathophysiology of heart failure with preserved ejection fractionK23HL109176 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUMMEL, SCOTT L · 2011 to 2015
$795k
NHLBI NIH HHS K23 HL109176NHLBI NIH HHS K23HL109176
6 · The paper itself

Abstract

The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly over the last two decades. In contrast, little or no progress has been made in identifying evidence-based, effective treatments for heart failure with preserved ejection fraction (HF-PEF). Despite the high prevalence, mortality, and cost of HF-PEF, large phase III international clinical trials investigating interventions to improve outcomes in HF-PEF have yielded disappointing results. Therefore, treatment of HF-PEF remains largely empiric, and almost no acknowledged standards exist. There is no single explanation for the negative results of past HF-PEF trials. Potential contributors include an incomplete understanding of HF-PEF pathophysiology, the heterogeneity of the patient population, inadequate diagnostic criteria, recruitment of patients without true heart failure or at early stages of the syndrome, poor matching of therapeutic mechanisms and primary pathophysiological processes, suboptimal study designs, or inadequate statistical power. Many novel agents are in various stages of research and development for potential use in patients with HF-PEF. To maximize the likelihood of identifying effective therapeutics for HF-PEF, lessons learned from the past decade of research should be applied to the design, conduct, and interpretation of future trials. This paper represents a synthesis of a workshop held in Bergamo, Italy, and it examines new and emerging therapies in the context of specific, targeted HF-PEF phenotypes where positive clinical benefit may be detected in clinical trials. Specific considerations related to patient and endpoint selection for future clinical trials design are also discussed.

Indexed as

AminobutyratesAnemiaAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsArrhythmias, CardiacBiphenyl CompoundsCardiotonic AgentsClinical Trials as TopicDiabetic AngiopathiesDiureticsDrug CombinationsExercise TherapyHeart FailureHomeostasisHumansHypertension, PulmonaryAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiphenyl CompoundsCardiotonic AgentsDiureticsDrug CombinationsMineralocorticoid Receptor AntagonistsPhosphodiesterase 5 Inhibitorssacubitril and valsartan sodium hydrate drug combinationSodium Channel BlockersTetrazolesValsartanClinical trialDiabetes mellitusExercise toleranceHeart failure, DiastolicPhenotypePreserved ejection fraction

Identifiers

PMID25104786
PMCPMC4204003
OpenAlexW2122465146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.